Hyperpigmentation Disorders Treatment Market

ID: MRFR/HC/5993-HCR

85 Pages

Vikita Thakur, Kinjoll Dey

Last Updated: May 15, 2026

色素沉着过度疾病治疗市场研究报告信息按治疗类型（热带药物、化学换肤和 Lesar 疗法）、按疾病适应症（黄褐斑和日光性雀斑）、最终用户（医院和其他）和按地区（北美、亚太地区、欧洲和世界其他地区）- 到 2032 年的市场预测

Hyperpigmentation Disorders Treatment Market Infographic

摘要目录分割方法论下载PDF

色素沉着过度治疗市场概览

p根据MRFR的分析，色素沉着过度治疗市场规模在2023年估计为5.6亿美元。预计色素沉着过度治疗市场规模将从2024年的5.9亿美元增长到2032年的9.3亿美元。预测期内（2024-2032年），色素沉着过度治疗市场的复合年增长率（CAGR）预计约为5.93%。预计在预测期内，对色素沉着过度治疗先进疗法的需求不断增长，将推动色素沉着过度治疗市场的发展。这些是推动色素沉着过度治疗市场发展的一些市场驱动因素。

色素沉着过度治疗市场

来源：二手资料研究、MRFR 数据库、一手资料研究和分析师评论

色素沉着过度治疗市场趋势

h3色素沉着过度治疗需求不断增长推动市场增长 p患有色素沉着过度治疗疾病的人数不断增加是色素沉着过度治疗市场增长的重要原因之一。印度、中国和其他亚洲国家有大量因色素沉着障碍而痛苦不堪的住院患者，这导致了对强效色素沉着障碍治疗方法的需求。因此，主要市场参与者积极参与研发，以刺激市场增长。此外，发达国家政府在生物技术和制药领域的巨额投入、医疗基础设施的扩展以及对色素沉着障碍治疗新方法的需求增长，预计将在预测期内推动色素沉着障碍治疗市场的发展。

此外，预计在研究期间，人们对色素沉着障碍的认识不断提高将促进市场增长。各政府机构已采取措施，提高人们对色素沉着障碍的认识。某些色素沉着无法治愈，例如白癜风和白化病，而且光疗费用高昂。处方药的价格也高得惊人。此外，根据治疗的皮肤区域，其他治疗（如激光治疗）的成本因恢复色素沉着而异。因此，预计许多色素沉着障碍治疗方法将与新疗法相结合。因此，这一因素在预测期内提高了色素沉着过度症治疗市场的复合年增长率。

图 1：全球色素沉着过度症治疗市场

来源：二手研究、MRFR 数据库、一手研究和分析师评论

然而，黄褐斑发病率的上升和对药妆治疗偏好的上升导致对皮肤病护理的需求大幅增加。 2020年，黄褐斑极为普遍，美国有超过500万人患有此病。亚洲育龄女性的患病率约为30%，治疗起来颇具挑战性。根据全球色素沉着过度症治疗市场趋势，预计未来几年治疗方案将持续增长。此外，色素沉着过度症治疗市场的一个重要趋势是，人们越来越关注安全有效的色素沉着过度症治疗方法的改进。由于色素沉着过度症的发病率上升以及对更优质治疗方法的需求增加，市场参与者正致力于开发和引入更安全的治疗方法。预计这种趋势将在预测期内持续下去，从而推动市场增长。

尽管如此，人们对多种皮肤病认识的提高导致了皮肤病治疗支出的增加，这与全球生活水平和人均收入的提高息息相关。这表明皮肤病治疗费用的增加，推动了预测期内全球色素沉着过度症治疗市场的增长。因此，预计这方面将推动全球色素沉着过度症治疗市场的收入。

色素沉着过度症治疗市场细分洞察

h3色素沉着过度症治疗类型洞察 p根据治疗类型，色素沉着过度症治疗的市场细分包括热带药物、化学换肤和激光疗法。热带药物领域在 2022 年的色素沉着过度症治疗市场数据中占据了大部分份额。由于色素沉着过度症患者的临床结果得到升级，局部治疗在全球市场占据主导地位。壬二酸、对苯二酚、L-抗坏血酸和其他外用药物是全球最常用的药物。

色素沉着过度症治疗疾病指征洞察

p根据疾病指征，色素沉着过度症治疗市场细分包括黄褐斑和日光性雀斑。黄褐斑细分市场在 2022 年主导了色素沉着过度症治疗市场的增长，预计在 2023-2032 年预测期内将成为增长最快的细分市场。黄褐斑目前在疾病类型领域中处于领先地位，因为它在白人中的发病率很高，占世界人口的 55% 至 60%。黄褐斑影响全球 90% 的女性，导致荷尔蒙波动、怀孕和避孕药物。

图 2：色素沉着过度障碍治疗市场，按疾病适应症，2022 年 2032（十亿美元）

来源：二手研究、MRFR 数据库、一手研究和分析师评论

色素沉着过度障碍治疗最终用户洞察

p基于最终用户的色素沉着过度障碍治疗市场数据包括医院和其他机构。 2022 年，医院细分市场占据了色素沉着过度症治疗市场收入的主导地位，预计在 2022-2030 年预测期内，该细分市场将成为增长最快的细分市场。这一细分市场的增长得益于皮肤科和美容诊所数量的增加。

然而，其他细分市场预计在预测期内也将增长。为了满足对色素沉着过度症治疗日益增长的需求，色素沉着过度症药妆品的生产商和经销商正在加强其供应链。

色素沉着过度症治疗区域洞察

p该研究按区域列出了北美、亚太地区、欧洲和世界其他地区色素沉着过度症治疗的市场洞察。2022 年，北美色素沉着过度症治疗市场规模为 46 亿美元，份额约为 45.80%，预计在预测期内将提高复合年增长率。色素沉着过度症发病率的上升是该地区增长的核心原因，因为该地区为此建立了医疗保健基础设施，并且主要市场参与者为炎症后色素沉着过度症患者提供有效的治疗选择。

此外，市场报告中研究的色素沉着过度症治疗重要国家是美国、加拿大、德国、法国、英国、意大利、西班牙、中国、日本、印度、澳大利亚、韩国和巴西。

图 3：2022 年各地区色素沉着过度症治疗市场份额（%）

2022 年各地区色素沉着过度症治疗市场份额

来源：二手资料研究、MRFR 数据库、一手资料研究及分析师评论

欧洲的色素沉着症治疗市场占据第二大市场份额，因为这些地区老年人口中色素沉着症的发病率很高，而欧洲是世界上老龄化最严重的地区之一，人口年龄在 65 岁及以上，这将对该地区市场构成挑战。此外，英国的色素沉着症治疗市场占有最大的市场份额，而德国的色素沉着症治疗市场是该地区增长最快的市场。

预计亚太地区色素沉着症治疗市场将在 2024 年至 2032 年期间以最快的复合年增长率增长。这归因于人们对色素沉着症认识的不断提高、医疗技术的快速发展、庞大的患者群体以及高昂的医疗支出。此外，中国色素沉着过度症治疗市场占有最大的市场份额，而印度色素沉着过度症治疗市场是该地区增长最快的市场。

色素沉着过度症治疗主要市场参与者和竞争洞察

p主要市场参与者正在投入大量资金进行研发，以增加其产品线，这将促进色素沉着过度症治疗市场的不断增长。竞争对手也在采取各种战略举措来扩大其全球影响力，关键的市场发展包括新产品发布、并购、合同协议、增加投资以及与其他组织的合作。色素沉着过度症治疗行业的市场参与者必须提供低成本的产品，才能在竞争激烈且日益增长的市场环境中扩张并渡过难关。

在全球色素沉着过度症治疗行业中，生产商为满足客户需求并扩大市场部门而采用的主要商业策略之一是缩小生产范围以降低运营成本。近年来，色素沉着过度症治疗行业提供了一些具有最显著益处的药物。色素沉着过度症治疗市场的重要参与者包括 Allergan, Inc.、Bayer AG、EpiPharm AG、Episciences、Galderma laboratories（雀巢皮肤健康公司）、SkinCeuticals International 等。

1863 年 8 月，染料销售员 Friedrich Bayer 和染色大师 Johann Friedrich Weskott 成立了普通合伙企业“Friedr. Bayer et comp.”，公司发展迅速。1881 年，拜耳转变为股份公司，为公司的扩张奠定了财务基础。该公司主要从事发现、丰富、生产和商业化用于人类健康和农业的产品。它提供用于治疗各种疾病、妇女健康、癌症、血液学、眼科和其他适应症的药物。它致力于开发用于治疗和现代农业的新分子和技术。

SkinCeuticals 由 Sheldon Pinnell 博士于 1997 年创立，总部位于纽约。该公司提供一系列护肤解决方案，如防晒霜、抗氧化剂、洁面乳、面膜、保湿霜、精华液和面霜，旨在改善皮肤健康。

色素沉着过度治疗市场的主要公司包括

Allergan

Bayer AG

EpiPharm AG

Episciences

Galderma laboratories（雀巢皮肤健康公司）

Obagi Cosmeceuticals LLC

Pierre Fabre

RXi Pharmaceuticals Corporation

SkinCeuticals International

Vivier Pharma

h3色素沉着过度治疗行业发展 p高德美实验室 (Galderma Laboratories) 同意与 Sol-Gel Technologies 达成独家许可协议，以商业化后者的在研药物产品，这些产品采用其专有的微胶囊技术。Sol-Gel Technologies 是一家临床阶段的皮肤病学公司，专门识别、开发和商业化用于治疗皮肤病的品牌和仿制外用药物产品。
2021 年 10 月： 知名公司 Uniza Healthcare 推出了一种名为 Vitellus 的新型疗法。该疗法是 EUK-134、Greyverse 和 Melitane GL 200 的独特组合，该公司与一家加拿大公司合作，在印度市场治疗白癜风。
色素沉着过度症治疗市场细分

色素沉着过度症治疗类型展望（十亿美元，2018-2030 年）

外用药物

化学换肤

激光疗法

色素沉着过度症治疗疾病适应症展望（十亿美元，2018-2030 年）

黄褐斑

日光性雀斑

色素沉着过度症治疗终端用户展望（十亿美元，2018-2030 年）

医院

其他

色素沉着过度症治疗区域展望（十亿美元，2018-2030 年）

北部美国

美国

加拿大

欧洲

德国

法国

英国

意大利

西班牙

其余部分欧洲

亚太地区

中国

日本

印度

澳大利亚

韩国

澳大利亚

亚太地区其他地区

世界其他地区

中东

非洲

拉丁美洲

市场亮点

Hyperpigmentation Disorders Treatment Companies

FAQs

What is the projected market valuation for the Hyperpigmentation Disorders Treatment Market in 2035?

The projected market valuation for the market in 2035 is 1.112 USD Billion.

What was the market valuation for the Hyperpigmentation Disorders Treatment Market in 2024?

The overall market valuation for the market was 0.59 USD Billion in 2024.

What is the expected CAGR for the Hyperpigmentation Disorders Treatment Market from 2025 to 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 5.93%.

Which segment is projected to have the highest valuation in the Hyperpigmentation Disorders Treatment Market?

The Melasma segment is projected to have the highest valuation, with estimates ranging from 0.3545 to 0.6465 USD Billion.

What are the key types of treatments available in the Hyperpigmentation Disorders Treatment Market?

Key types of treatments include Topical Drugs, Chemical Peels, and Laser Therapy, with Topical Drugs valued at 0.25 to 0.45 USD Billion.

Who are the leading companies in the Hyperpigmentation Disorders Treatment Market?

Leading companies in the market include Galderma, L'Oreal, Estée Lauder, and Johnson & Johnson.

What is the projected valuation for the Chemical Peels segment by 2035?

The projected valuation for the Chemical Peels segment is expected to range from 0.15 to 0.3 USD Billion.

How does the market for Solar Lentigines compare to Melasma in terms of valuation?

The Solar Lentigines segment is projected to have a valuation ranging from 0.2355 to 0.4655 USD Billion, which is lower than that of Melasma.

What is the expected growth trend for hospitals as an end user in the Hyperpigmentation Disorders Treatment Market?

The hospitals segment is projected to grow, with valuations expected to range from 0.35 to 0.65 USD Billion.

What is the significance of the Others segment in the Hyperpigmentation Disorders Treatment Market?

The Others segment is projected to have a valuation ranging from 0.24 to 0.462 USD Billion, indicating its relevance in the overall market.

作者

Author

Vikita Thakur

Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Co-Author

Kinjoll Dey

Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

取得联系

发表评论

认证研究员

定制报告

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Global Health Observatory, International Agency for Research on Cancer (IARC), American Academy of Dermatology (AAD), European Centre for Disease Prevention and Control (ECDC), Pan American Health Organization (PAHO), UNFPA, Indian Council of Medical Research (ICMR), Japan Ministry of Health Labour and Welfare (MHLW), Health Canada, and national health ministry reports from key markets. These sources were used to collect disease prevalence statistics, regulatory approval data for topical agents and laser devices, clinical safety studies, demographic trends, and market landscape analysis for melasma, solar lentigines, and other hyperpigmentation disorders.

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from pharmaceutical, medical device, and skincare OEMs were examples of supply-side sources. Board-certified dermatologists, plastic surgeons, medical spa directors, and procurement leaders from hospitals, specialty & dermatological clinics, and cosmetic centers were among the demand-side sources. Primary research obtained information on clinical adoption trends, pricing tactics, and reimbursement dynamics in addition to validating market segmentation and product pipeline deadlines.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

Market Size Estimation

Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across topical drugs (hydroquinone, retinoids, azelaic acid, kojic acid, vitamin C), chemical peels (glycolic acid, salicylic acid, TCA), and laser therapy (Q-switched, fractional, IPL) categories

Analysis of reported and modeled annual revenues specific to hyperpigmentation treatment portfolios

Coverage of manufacturers representing 70-75% of global market share in 2024

Extrapolation using bottom-up (procedure volume × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations

下载免费样本

请填写以下表格以获取本报告的免费样本

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

案例研究

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓